Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.52 |
| ▸ | NRP1 | O14786 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.45 |
| ▸ | CALCR | P30988 | 3/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30844324 | 0.96 | OPRM1 (0.51) | OPRM1OPRK1NRP1APLNRCXCR4 | |
| SCHEMBL29572497 | 0.94 | OPRM1 (0.55) | OPRM1OPRK1APLNRCXCR4 | |
| SCHEMBL29723642 | 0.93 | OPRM1 (0.51) | OPRM1OPRK1NRP1APLNRCXCR4 | |
| SCHEMBL29571627 | 0.93 | NRP1 (0.54) | OPRM1OPRK1NRP1CXCR4 | |
| SCHEMBL29802012 | 0.91 | ACE (0.48) | OPRM1NRP1APLNR | |
| SCHEMBL29801770 | 0.91 | OPRM1 (0.48) | OPRM1OPRK1NRP1APLNRCXCR4 | |
| SCHEMBL29802094 | 0.91 | OPRM1 (0.45) | OPRM1OPRK1NRP1RAMP3CALCR | |
| SCHEMBL30689127 | 0.90 | OPRM1 (0.50) | OPRM1OPRK1NRP1APLNRCXCR4 | |
| SCHEMBL22872708 | 0.90 | NRP1 (0.54) | OPRM1OPRK1NRP1EPHA2 | |
| SCHEMBL31088262 | 0.89 | RAMP3 (0.48) | OPRM1OPRK1RAMP3CALCREPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3359554-B1 | PEPTIDES OF USE IN THE PREVENTIVE AND CURATIVE TREATMENT OF ALOPECIA | INST EUROPEEN DE BIOLOGIE CELLULAIRE (FR) | 2026-04-22 | — | — | EP | claimed |
| EP-4306534-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | Wuhan Innerse Pharmaceutical Inc. (CN) | 2024-01-17 | — | — | EP | claimed |
| WO-2022188878-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | 武汉英纳氏药业有限公司 | 2022-09-15 | — | — | WO | claimed |
| CN-110615828-B | 1S-methyl-beta-tetrahydrocarboline acyl-K and synthesis, activity and application thereof | 首都医科大学 | 2022-09-02 | — | — | CN | claimed |
| CN-108602853-B | Peptide for preventing and radically treating alopecia | 欧洲细胞生物学研究所 | 2022-05-31 | — | — | CN | claimed |
| CN-111995661-B | Ethyl ARPAK modified bis-carbolino-piperazinediones, preparation, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | claimed |
| EP-3359554-B1 | PEPTIDES OF USE IN THE PREVENTIVE AND CURATIVE TREATMENT OF ALOPECIA | INST EUROPEEN DE BIOLOGIE CELLULAIRE (FR) | 2026-04-22 | — | — | EP | disclosed |
| CN-118459544-A | PAK sequence peptide modified diindolylmethane derivative and preparation and application thereof | 首都医科大学 | 2024-08-09 | — | — | CN | disclosed |
| EP-4306534-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | Wuhan Innerse Pharmaceutical Inc. (CN) | 2024-01-17 | — | — | EP | disclosed |
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2022188878-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | 武汉英纳氏药业有限公司 | 2022-09-15 | — | — | WO | disclosed |
| CN-110615828-B | 1S-methyl-beta-tetrahydrocarboline acyl-K and synthesis, activity and application thereof | 首都医科大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-110615828-B | 1S-methyl-beta-tetrahydrocarboline acyl-K and synthesis, activity and application thereof | 首都医科大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-108602853-B | Peptide for preventing and radically treating alopecia | 欧洲细胞生物学研究所 | 2022-05-31 | — | — | CN | disclosed |
| CN-111995661-B | Ethyl ARPAK modified bis-carbolino-piperazinediones, preparation, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | disclosed |
| CN-111995661-B | Ethyl ARPAK modified bis-carbolino-piperazinediones, preparation, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SERPINC1, PLAT, F2 | OPRM1 3249/4885OPRK1 2963/4885NRP1 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.